Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal
RZV presents a cost-effective option for the prevention of HZ and its complications in Portuguese adults aged ≥ 65 years, with greater cost effectiveness in those aged 65-69 years.
Authors
- Eleftherios Zarkadoulas (ORCID: https://orcid.org/0009-0003-6940-6367)
- Maarten J. Postma
- Fabio Luiz Carneiro Mourilhe Silva
- Joana Alves
- Francisco Madeira
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Universitas Airlangga (ID)
- GlaxoSmithKline (Belgium) (BE)
- Universidade Nova de Lisboa (PT)
- Padjadjaran University (ID)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2026-03-02
- DOI
- https://doi.org/10.1007/s41669-026-00640-3
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00